Vogelmeier, Claus F.
Kostikas, Konstantinos
Fang, Juanzhi
Tian, Hengfeng
Jones, Bethan
Morgan, Christopher Ll
Fogel, Robert
Gutzwiller, Florian S.
Cao, Hui
Funding for this research was provided by:
Novartis Pharma AG (N/A)
Article History
Received: 13 March 2019
Accepted: 8 July 2019
First Online: 7 August 2019
Ethics approval and consent to participate
: CPRD provided data for this study. Studies using CPRD are covered by ethics approval provided by Trent multicentre research ethics committee (reference: 05/MRE04/87). This study was granted CPRD Independent Scientific Advisory Committee approval (ISAC 17_213).
: Not applicable
: CFV reports research support from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Grifols, Novartis, Bayer Schering, MSD, Pfizer, consultancy from AstraZeneca, Boehringer Ingelheim, CSL Behring, GlaxoSmithKline, Grifols, Menarini, Novartis, Teva, Cipla, and honoraria from AstraZeneca, Boehringer Ingelheim, CSL Behring, GlaxoSmithKline, Grifols, Menarini, Mundipharma, Novartis, Teva, Cipla. KK was an employee of Novartis Pharma AG at the time of the conduct of this study. JF is an employee of Novartis Pharmaceuticals Corporation owning stocks through the employment. HT is employee of KMK Consulting Inc. and providing consulting to Novartis, the sponsor of the study. BJ is an employee of Pharmatelligence who received funding from Novartis to conduct analyses for this study. CM is a consultant of Pharmatelligence who received funding from Novartis to conduct analyses for this study. RF is an employee of Novartis Pharmaceuticals Corporation owning stocks through the employment. FSG is an employee of Novartis Pharma AG owning stocks through the employment. HC is an employee of Novartis Pharmaceuticals Corporation owning stocks through the employment.